Dyke-Yang Congenital Hemolytic Anemia

Dyck-Yang congenital hemolytic anemia (CHA) is a rare hereditary disease characterized by increased destruction of red blood cells and a decrease in the amount of hemoglobin in the blood. This leads to anemia, jaundice and an enlarged spleen.

DYAD is caused by a disorder of nucleotide exchange in the gene encoding the band 3 protein, which is part of the red blood cell membrane. This leads to disruption of the membrane structure and increased tendency to destruction.

The disease can manifest in newborns or early childhood, and can lead to serious complications such as jaundice, hyperbilirubinemia, aplastic crisis, hypospherocytosis and others. Diagnosis of DUAVH is based on clinical data, biochemical and genetic studies.

Treatment of DYAVG is aimed at improving the patient’s condition and preventing complications. This may include blood substitutes, blood transfusions, immunomodulators, and folic acid and antibiotic therapy to prevent infections.

Overall, Dyck-Yang congenital hemolytic anemia is a serious condition that requires close monitoring and treatment. Early diagnosis and treatment can help prevent serious complications and improve patients' quality of life.

**Dyke-Young** is a congenital hemorrhagic anemia, which is characterized by severe recurrent bleeding and hemolysis. It usually appears in children at an early age and is often severe. If left untreated, it can be fatal.

The name "Dyke - Young" is a combination of the names of the researchers who first described this